BeOne Medicines Showcases Promising Hematology Pipeline Data at EHA 2026, Highlighting Advances in BTK Degradation and Time-Limited Therapies BeOne Medicines Ltd., a global oncology company focused on developing innovative treatments for cancer and hematologic malignancies, has unveiled a series of…
BeOne Medicines Showcases Long-Term BRUKINSA Success and Next-Generation CLL Treatment Advances at ASCO 2026 BeOne Medicines Ltd., a global oncology company dedicated to developing innovative cancer therapies, is presenting extensive new data at the 2026 American Society of Clinical Oncology…
BeOne Medicines Reports Phase 3 HERIZON-GEA Results Published in NEJM and Featured at ASCO 2026 BeOne Medicines has announced the publication and upcoming presentation of significant new clinical data from the HERIZON-GEA-01 trial evaluating ZIIHERA in combination with chemotherapy, with…
BeOne Medicines Showcases More Than 60 Abstracts at ASCO and EHA 2026 BeOne Medicines announced that it will present more than 60 scientific abstracts at two of the world’s most influential oncology and hematology conferences in 2026, reinforcing the company’s…
BeOne Medicines Showcases Expanding Oncology Pipeline With More Than 60 Presentations at ASCO and EHA 2026 BeOne Medicines Ltd. has announced a major presence at two of the world’s leading oncology conferences in 2026, highlighting the company’s rapidly expanding influence…
TRIANA Biomedicines Appoints Mohan Bala as COO and Expands Scientific Advisory Board With Industry Experts TRIANA Biomedicines has announced a series of major leadership and scientific advisory appointments as the company continues expanding its molecular glue degrader platform and advancing…
Parabilis Medicines Partners With Regeneron Pharmaceuticals to Develop Antibody-Helicon™ Conjugates Across Multiple Diseases Parabilis Medicines has entered into a major strategic research collaboration with Regeneron Pharmaceuticals aimed at advancing a new generation of targeted medicines designed to tackle some of…
BeOne Medicines’ BEQALZI™ Receives U.S. FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines has announced that the U.S. Food and Drug Administration has granted accelerated approval to BEQALZI for the treatment of adult…
Ray Therapeutics Secures PRIME Designation from the European Medicines Agency for RTx-015 Targeting Retinitis Pigmentosa Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company focused on developing innovative therapies for vision restoration, has announced that the European Medicines Agency (EMA) has granted…
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of its concurrent public…
Bepirovirsen advances to regulatory review by the European Medicines Agency as a promising first-in-class therapy for chronic hepatitis B GSK plc has announced a significant regulatory milestone as the European Medicines Agency (EMA) has formally accepted for review its marketing…
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…